Belantamab mafodotin (NCT07227311)

Name: Belantamab mafodotin trial for Multiple Myeloma (NCT07227311)
Uploaded: 2026-10-31T21:38:02.357Z
Duration: 1 min 18 s
Description: Belantamab mafodotin trial for Multiple Myeloma (NCT07227311). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07227311.

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM): a one-minute explainerNCT072273111 min

Belantamab mafodotin trial for Multiple Myeloma (NCT07227311). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with multiple myeloma progressing after one or two treatment lines, without previous BCMA-directed therapy. Each group has additional treatment-history requirements.

The idea: belantamab mafodotin targets BCMA and carries a drug that disrupts cell division. Researchers test less frequent dosing with dexamethasone and either pomalidomide, bortezomib, or carfilzomib in separate groups. Assignment is not random. They measure responses and safety, including eye effects. Reduced eye toxicity is not assured.

This phase 2 study plans 200 patients. GSK sponsors the study; 12 US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.